Clinical trials: Skin Sensitivity
Atopic Dermatitis
Efficacy and Safety of PR022 Topical Gel to Treat Mild-to-Moderate Atopic Dermatitis
The purpose of this study is to determine whether PR022 Topical Gels are safe and effective treatments for mild-to-moderate atopic dermatitis (AD).
- Trial name
- NCT03351777
- Testing
- PR022
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Realm Therapeutics, Inc.
Atopic Dermatitis
A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants
The purpose of this study is to see how a medicine called PF-08049820 affects how other medicines move through the body. This information will help plan future studies.
- Trial name
- NCT07190430
- Testing
- PF-08049820, Midazolam, Dabigatran Etexilate
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Angioedema
A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor
The purpose of this study is to evaluate the long-term safety and efficacy of repeated subcutaneous (SC) administration of lanadelumab in adolescents and adults with non-histaminergic angioedema with normal C1-inhibitor who…
- Trial name
- NCT04444895
- Testing
- Lanadelumab
- Where
- 35 sites in United States, Canada and 8 more
- Volunteers
- 73 people
- Sponsor
- Shire
Atopic Dermatitis
A Phase 2 Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis
The purpose of this study is to assess efficacy, safety, and pharmacokinetics (PK) of QLM3003 Ointment in participants with mild or moderate atopic dermatitis.
- Trial name
- NCT06058000
- Testing
- 1.5% QLM3003, 2% QLM3003
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Dermatitis, Atopic
Study Of Single And Ten Day Repeat Atopical Applications Of GW842470X Cream On The Skin Of Patients With Atopic Dermatitis
The purpose of this study of this study is to investigate the safety, tolerability and pharmacokinetics of GW842470X in patients with atopic dermatitis. GW842470X is an inhibitor of phosphodiesterase 4 (PDE4).
- Trial name
- NCT00356642
- Testing
- GW842470X
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- GlaxoSmithKline
Moderate-to-severe Atopic Dermatitis
A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis
The goal of this clinical trial is to evaluate the efficacy and safety of JYP0061 in adult patients with moderate-to-severe atopic dermatitis.
- Trial name
- NCT06158490
- Testing
- JYP0061 15 mg, JYP0061 30 mg
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Guangzhou JOYO Pharma Co., Ltd
Hereditary Angioedema (HAE)
Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)
The purpose of this study is to determine if a subcutaneous dose of DX-88 (ecallantide; an investigational product) is safe and relieves symptoms of HAE in patients suffering from moderate to severe acute attacks of HAE.
- Trial name
- NCT00262080
- Testing
- ecallantide, Phosphate Buffer Saline (PBS),
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Shire
Atopic Dermatitis
Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement
This is a randomized, double blind, vehicle controlled Phase 2 study with a 4-week open label extension in adolescent and adult participants with atopic dermatitis and head and/or neck involvement.
- Trial name
- NCT05127421
- Testing
- Ruxolitinib cream, Vehicle
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis
A Safety, Tolerability and Pharmacokinetic Study of LEO 29102 in Subjects With Atopic Dermatitis
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of 7 days treatment with LEO 29102 in adult patients with atopic dermatitis.
- Trial name
- NCT01005823
- Testing
- LEO 29102 cream
- Where
- Netherlands
- Volunteers
- 36 people
- Sponsor
- LEO Pharma
Chronic Urticaria, Idiopathic
A Phase 2 Study of MG-K10 in Chronic Spontaneous Urticaria
This Phase 2 study evaluates the efficacy and safety of MG-K10 in participants with chronic spontaneous urticaria inadequately controlled by second-generation H1-antihistamines.
- Trial name
- NCT07838727
- Testing
- MG-K10 Injection
- Volunteers
- 60 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Atopic Dermatitis, Sleep Disturbance
A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis
Many people with atopic dermatitis (AD) experience sleep disturbances. Greater sleep disturbances are associated with greater burden including increased sick days and impaired cognition.
- Trial name
- Sleep Up (NCT06390722)
- Testing
- Upadacitinib
- Sponsor
- AbbVie
Atopic Dermatitis
HL-300 Ointment in Healthy Volunteers
To evaluate the safety and tolerability of HL-300 ointment following single and multiple topical administrations in healthy Chinese adult volunteers.
- Trial name
- NCT07684937
- Testing
- HL-300
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Hereditary Angioedema (HAE)
Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of DX-2930 in preventing acute angioedema attacks in patients with Type I and Type II HAE.
- Trial name
- NCT02586805
- Testing
- DX-2930 - 300mg/2wk, DX-2930 - 300mg/4wk, DX-2930 - 150mg/4wk
- Where
- 41 sites in United States, Canada and 5 more
- Volunteers
- 125 people
- Sponsor
- Shire
Atopic Dermatitis
Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis (AD)
The purpose of phase I clinical trial is to evaluate safety and efficacy in subjects with over Moderately subacute and chronic Atopic Dermatitis after inject.
- Trial name
- NCT01927705
- Testing
- FURESTEM-AD Inj.
- Where
- South Korea
- Volunteers
- 34 people
- Sponsor
- Kang Stem Biotech Co., Ltd.
Atopic Dermatitis
Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis
To assess the efficacy and safety of MEDI9929 in adult subjects with Atopic Dermatitis
- Trial name
- ALLEVIAD (NCT02525094)
- Testing
- MEDI9929
- Where
- 29 sites in United States, Australia and 4 more
- Volunteers
- 113 people
- Sponsor
- MedImmune LLC
Atopic Dermatitis
Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis
The purpose of this study is to evaluate the efficacy and safety of baricitinib as monotherapy in participants with moderate to severe atopic dermatitis.
- Trial name
- BREEZE-AD2 (NCT03334422)
- Testing
- Baricitinib
- Where
- 80 sites in Argentina, Australia and 8 more
- Volunteers
- 615 people
- Sponsor
- Eli Lilly and Company
Allergic Rhinitis, Urticaria
Effects of Bilastine on F1 Simulator Driving Performance in Patients Affected by Allergic Rhinitis and/or Urticaria
The aim of the study is to evaluate the effects of Bilastine on patients' attention and reactivity levels by measuring psychophysical performance at a F1-high speed simulator driving test.
- Trial name
- F1 (NCT02576041)
- Testing
- Bilastine
- Where
- Italy
- Volunteers
- 19 people
- Sponsor
- Menarini International Operations Luxembourg SA
Atopic Dermatitis, Eczema
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to <18 years of age with moderate-to-severe atopic dermatitis.
- Trial name
- ADorable-2 (NCT05735483)
- Testing
- Lebrikizumab
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 338 people
- Sponsor
- Eli Lilly and Company
Sensitive Skin, Non-sensitive Skin
A Clinical Investigation Into the Association of an Impaired Skin Barrier and Infant and Toddler Sensitive Skin
This is a Single center, evaluator-blinded clinical trial that intends to • Evaluate differences in TEWL measurements between parent-reported sensitive skin subjects and healthy subjects (subjects without sensitive skin) •…
- Trial name
- NCT07225166
- Testing
- Expert Clinical Grading, Instrumental Measurements, Parental Questionnaires
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Kenvue Brands LLC
Atopic Dermatitis
Evaluation of the Efficacy of a Dermocosmetic Product RT00401-GO0046 on Atopic Dermititis Severity in Subjects With Mild Atopic Dermatitis Versus Placebo
The aim of this study is to evaluate the RT00401- GO0046 formula on atopic dermititis severity in subjects with mild atopic dermatitis versus placebo on 26 subjects.
- Trial name
- NCT06763939
- Testing
- RT00401-GO0046, RT00401-GA0677
- Where
- Poland
- Volunteers
- 32 people
- Sponsor
- Pierre Fabre Dermo Cosmetique